Skip to main content
Sage's major depressive disorder drug given FDA breakthrough status
2/8/2018

Sage Therapeutics' SAGE-217, which is being assessed in a late-stage study for the treatment of patients with major depressive disorder, was granted breakthrough therapy status by the FDA.

Full Story: